Total Q1 gold demand, including OTC, was 2% higher y/y at 1,231t. Geopolitical factors are expected to remain front and ...
Erasca's share price nosedived 53% after a patient died in its Phase I trial of ERAS-0015, and rival Revolution Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results